Key Takeaways
- Revenue raised, margin raised: 24% YoY top-line growth to ₹2,820 crores prompted management to lift FY27 revenue guidance to exceed 20%, with EBITDA margin now expected at the upper end of the 75–100 bps improvement range.
- India hits double digits again: Domestic business grew 12% YoY, the second straight quarter of double-digit growth, with organic growth accelerating to 10% from 6% in Q1.
- International is now 59% of the company: 34.5% YoY growth to ₹1,665 crores, driven by base business expansion and new launches across Europe, Canada and RoW.
- Zuventus has turned the corner: After a year of stability and consolidation following a massive rep exodus, management says the subsidiary is now in acceleration phase and expects overall domestic business to exit FY27 at or above industry growth.
- What to watch next quarter: Whether the raised guidance holds through H2, the pace of amphotericin B launches in newly approved emerging markets, and any supply resolution on semaglutide in Canada.
India Business: Recovery & Trajectory
- Organic growth accelerating: Base business ex-Zuventus continues to grow faster than the industry; organic growth improved to 10% from 6% in Q1, driven by women's health, cardiometabolic and CNS portfolios.
- Zuventus in acceleration phase: Management described three phases (stability, consolidation, acceleration) and stated the first two are behind them; key brands are showing good traction and sequential improvement has been significant.
- Full-year exit ambition: Expect domestic growth to be at or above industry growth by FY27 exit, with overall domestic growth closer to low teens for the full year, and second half more in line with the industry.
- MR productivity rising: Productivity per rep improved QoQ without increasing MR headcount, and the company is not looking to add new reps in the near term.
- Hospital business small: Hospital contribution to domestic formulations remains in single digits; the focus stays on prescription generation in trade.
- IPM growth tied to the economy: Management's historical rule of thumb is that pharma industry growth runs at 1.5x economic growth, implying 11–12% IPM growth when GDP grows at 8%.
Mehta: "in my 30 years of association with the domestic market, once the economic growth picks up, normally, I have seen the growth of the pharma industry is 1.5x that of the economic growth that we have. So, if you are growing at 8%, 12% is granted, it is going to happen, 11%, 12%."
International: Geography Mix & Drivers
- Europe leads: 36% YoY growth to ₹604 crores, broad-based across base portfolio, new launches and continued scale-up of liposomal amphotericin B.
- Canada steady: 24% YoY growth to ₹431 crores, driven by base business and recent launches; further launches expected in H2 with a strong pipeline being built.
- RoW diversifying fast: 41% YoY growth to ₹630 crores; ARV share in RoW dropped from ~67% last quarter to ~50% this quarter, signalling strong non-ARV acceleration from new launches and portfolio expansion in Latin America, CIS, Asia and Africa.
- Constant currency vs reported: International grew ~24% in constant currency, with ~10% currency headwind bringing reported growth lower.
- Amphotericin B manufacturing de-risked: Two manufacturing sites now operational, each broken out by market served; recent regulatory agency audits all closed, and UK has approval at both sites.
- Emerging market launches imminent: Approvals received in Brazil, Colombia and Mexico; batches already under production, and at least a couple of markets should launch across the next half.
- Penetration runway: Amphotericin B has penetrated about 50% of the addressable market, with roughly 20 countries still to enter.
Product Pipeline & Key Assets
- Lenacapavir progressing: Received positive recommendation from India's Subject Expert Committee for PrEP indication; dossier filed with WHO and U.S. FDA for RoW markets; expected to be an important, margin-accretive part of the ARV portfolio in the medium term.
- Poviztra gaining rank: Ranked number 4 brand per IQVIA in the last month; October numbers suggest rank improvement by at least one position.
- Treprostinil in Europe: Expected to contribute significantly, with limited competition, an attractive market, and strong value and margin profile.
- Semaglutide Canada waiting on supply: Partner Dr. Reddy's has indicated supply possibly in November; Emcure ready to launch when supplies arrive; filing expected this fiscal, likely in the next few months.
- Over 20 product approvals in Q2: Including liposomal amphotericin B in Brazil and Mexico, and bevacizumab for wet AMD in India.
Mehta: "It's not really going to happen in a day, but we obviously see ourselves a long-term player in this particular market and things are happening in the right direction. It's not earth-shattering the way it was felt some time back, but we are right there."
Margins & Cost Structure
- EBITDA margin expansion: Rose ~100 bps YoY to 20.4%, driven by productivity gains and operating leverage; gross margin improved ~110 bps QoQ to 59.5% on business and product mix.
- Input cost pressure contained: Rising imported raw material costs, freight, insurance and increased transit times were partially offset by favourable currency, leaving the overall gross margin impact relatively muted.
- SG&A leverage path: Margin improvement expected to come from operating leverage, with SG&A growth targeted to be slower than revenue growth.
- R&D spend within range: Full year expected within 4–5% of revenue; H2 R&D will step up but remain inside that bracket.
- Other income declined: Dropped to ₹16 crores from ₹39 crores last year, primarily on lower foreign exchange gains.
- Finance cost rising: ₹36 crores, reflecting increased borrowings to fund acquisition-related payouts.
Thapar: "on the one hand, we benefited from some favourable currency impact. On the other side, I think some of these costs are wiping out a big chunk, if not most of those gains. So that's why, I think, overall, our gross margin impact has been relatively muted. But certainly, we have been seeing, in many cases, some rising input costs."
Balance Sheet & Capital Allocation
- Net debt up on M&A payouts: Increased ₹263 crores over March '26 to ₹1,317 crores; H1 acquisition-related payouts of ₹551 crores covered the final Canada payout, Genova minority stake and a UK product portfolio.
- Net cash ambition maintained: Management remains committed to becoming net cash by end of FY28.
- Corporate simplification underway: Board approved amalgamation of Zuventus Healthcare and Emcutix Biopharmaceuticals into Emcure, part of the "One Emcure" vision to simplify the group holding structure; subject to NCLT and other approvals.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Exceed 20% (raised from mid-teens) | FY27 full year |
| EBITDA margin improvement | Upper end of 75–100 bps range | FY27 full year |
| Domestic organic growth | At or above industry growth | By FY27 exit |
| Zuventus growth | In line with IPM growth | By end of FY27 |
| R&D spend | Within 4%–5% of revenue | FY27 full year |
| Net debt | Become net cash | By end of FY28 |
| Amphotericin B emerging market launches | At least a couple of markets launching | Next half (H2 FY27) |
| Semaglutide Canada filing | File in next few months | This fiscal (FY27) |
| Manufacturing capacity | Facilities able to cater without restriction | Next 18–24 months |
| ARV share of RoW | 50%–55% of RoW sales | FY27 full year |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹2,820 cr, up 24.3% YoY and 9.3% QoQ |
| India revenue | ₹1,155 cr, up 12% YoY; organic growth 10% vs 6% in Q1 |
| International revenue | ₹1,665 cr, up 34.5% YoY, 59% of total revenue |
| Europe revenue | ₹604 cr, up 36% YoY |
| Canada revenue | ₹431 cr, up 24% YoY |
| Rest of World revenue | ₹630 cr, up 41% YoY |
| EBITDA | ₹575 cr, up 31% YoY |
| EBITDA margin | 20.4%, expanded ~100 bps YoY and ~70 bps QoQ |
| PAT | ₹325 cr, up 29% YoY; PAT margin 11.5%, improvement of 45 bps |
| Gross margin | 59.5%, QoQ improvement of ~110 bps |
| R&D spend | ₹111 cr, ~4% of revenue from operations |
| Net debt | ₹1,317 cr as of September, increase of ₹263 cr over March '26 |
| H1 acquisition-related payouts | ₹551 cr, including final Canada payout, minority stake in Genova, UK product portfolio payment |
| Overall constant currency growth | 18.5%; international constant currency growth ~24% |
| ARV share of Rest of World revenue | ~50%, down from 67% in Q1 |
| Full-year FY27 revenue growth guidance | Exceed 20%, raised from mid-teens earlier |
| Full-year FY27 EBITDA margin guidance | Upper end of 75–100 bps improvement range |